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Introduction
Syncope is defined as a sudden, but transient loss of consciousness accompanied by a loss of postural tone. Recovery is spontaneous and does not require the use of cardiopulmonary resuscitation. Syncope is a common condition and the differential diagnosis is extensive. It has been reported that the frequency of syncope amongst users of emergency departments in Europe is approximately 1% [1, 2] . The causes of syncope are frequently benign, but can occasionally be due to a potentially life-threatening disorder [3] . Because of the transient nature of syncope and some of its causes, determination of the underlying mechanism can be challenging. A comprehensive initial clinical history along with a detailed physical examination and an electrocardiogram (ECG) are essential for determining the possible causes as well as the need for further diagnostic testing. However, despite a thorough evaluation, the cause of syncope may remain unknown in approximately a third of patients.
The causes of syncope are heterogeneous and vary with age (Table 1) . Neurocardiogenic (vasovagal) syncope is most common in patients under the age of 40 years and usually has a favourable prognosis [4] . More serious, but less frequent causes of syncope in those under the age of 40 include hypertrophic cardiomyopathy and the so-called primary electrophysiological disorders, which can result in ventricular tachycardia (VT) and fibrillation [5] . In individuals over the age of 40 years, cardiac mechanical causes, such as heart failure and aortic stenosis, in addition to arrhythmias are more common [6] . Furthermore, conditions such as orthostatic hypotension and drug-related syncope are not uncommon in older age groups. In the elderly, syncope is also more commonly due to a combination of factors. The presence of structural heart disease increases the likelihood of a serious cause of syncope, such as malignant ventricular arrhythmias.
There are two main goals in the evaluation of patients with syncope. The first aim is to establish the cause of the syncopal event. Secondly, patients are stratified according to risk, including identification of those at high risk of sudden cardiac death or of recurrent syncope or physical injury [5, 6] .
High-risk features of syncope
Cardiac syncope can predict sudden cardiac death [7] . Individuals who present with syncope and are at high risk of subsequent sudden cardiac death, frequently have a history of structural heart disease along with clinical or ECG characteristics suggestive of a serious arrhythmia [6] . These characteristics include heart failure with a severely reduced ejection fraction or the presence of myocardial scar tissue from previous myocardial infarction. Clinical features suggestive of a serious cause of syncope include occurrence during either exertion or whilst supine. Prodromal symptoms of chest pain, acute shortness of breath and palpitations with sudden onset of dizziness may all suggest a possible serious cardiac cause. A higher risk of sudden cardiac death is also indicated by an ECG showing one or more of the following abnormalities: nonsustained VT, bifascicular block or intraventricular conduction delay (QRS > 120 ms), a pre-excited QRS, abnormally prolonged or short QT interval, a Brugada syndrome pattern or negative T waves in the precordial leads along with an epsilon wave consistent with arrhythmogenic right ventricular cardiomyopathy [6, 8] . Patients presenting with syncope and one or more of the above ECG abnormalities are candidates for hospital admission. These individuals should receive continuous ECG monitoring and further diagnostic evaluation whilst in hospital; consultation with an arrhythmia specialist should also be considered.
A diagnosis of a cardiac cause of syncope has important prognostic implications. Studies comparing mortality after syncope according to likely mechanism have consistently shown that patients with a cardiac cause have a higher mortality than those with a noncardiac cause [9] . In the largest such study of over 400 patients with a follow-up of more than 60 months, the mortality rate during follow-up was 50% in patients with a cardiac cause compared with rates of 31% and 24%, respectively, in those with a noncardiac or unknown cause [10] .
A variety of structural heart diseases can result in syncope (Table 2 ) [6] . Disorders commonly associated with syncope include ischaemic heart disease (especially if associated with depressed left ventricular function), nonischaemic dilated cardiomyopathy and severe aortic stenosis. Other less frequent, but nevertheless important causes are hypertrophic cardiomyopathy and arrhythmogenic right ventricular cardiomyopathy (previously termed dysplasia). Although not classified as structural heart diseases, but rather as genetic disorders that underlie primary electrophysiological disease, the long QT interval syndrome (LQTS), short QT syndrome, catecholaminergic polymorphic VT and Brugada syndrome are also worth considering as relatively infrequent, but serious causes of syncope. Similarly, an accessory atrioventricular pathway causing delta wave on the ECG may represent uncommon causes of severe syncope. In the latter case, atrial fibrillation can be associated with extremely high ventricular rates due to rapid conduction over the accessory pathway, which may sometimes lead to syncope and even cardiac arrest.
Myocarditis, pulmonary embolism, cardiac tamponade, atrial myxoma, severe pulmonary hypertension and certain congenital heart diseases (including those previously repaired) are structural heart disorders that are occasionally associated with syncope [6] .
A family history of sudden cardiac death, especially at a young age, should alert to the possibility of an inherited arrhythmogenic disease [5] . Likewise, However, it is noteworthy that the presence of structural heart disease per se does not necessarily imply that the syncopal event is caused by the underlying heart disorder. Patients with an underlying heart condition can also have relatively benign causes of syncope, such as neurocardiogenic or drug-induced syncope. Druginduced syncope can be overlooked, especially in elderly patients who may be taking a number of different cardiac medications [11] . Frequently used drugs amongst patients with heart disease include beta blockers, diuretics and vasodilators. All these drugs could alone or in combination predispose patients to episodes of haemodynamic compromise due to bradycardia and/or hypotension in different clinical situations. Furthermore, the use of antiarrhythmic medications can be associated with proarrhythmia and syncope, or even cardiac arrest. A complete medication history including recently started prescription and over the counter drugs should therefore always be obtained.
Mechanisms of syncope in structural heart disease
The most frequent cause of syncope in patients with structural heart disease are arrhythmias causing decreased cardiac output, haemodynamic impairment and a subsequent decrease in cerebral blood flow [3] . Both bradyarrhythmias and tachycardias can lead to syncope. There are a number of factors that determine whether or not a tachyarrhythmia leads to syncope, including the type of arrhythmia [12] . In this regard, supraventricular tachyarrhythmias are generally better tolerated than VTs and the faster the heart rate during the arrhythmia, the less well it is tolerated. Patients with impaired left ventricular ejection fraction are usually less able to tolerate fast heart rhythms. The posture of a patient during the onset of the arrhythmia also has an influence on tolerability. Finally, the use of vasoactive drugs may adversely affect the haemodynamic response during tachycardia.
Bradycardia due to sick sinus syndrome or advanced atrioventricular block is another common cause of syncope in patients with heart disease. Interruption of cerebral blood flow for 8-10 s usually produces loss of consciousness, although briefer pauses can cause near syncope [7] . In individuals with a pacemaker, a device malfunction needs to be ruled out.
Other possible causes of cardiogenic syncope include low output states, for example with either ischaemic or dilated cardiomyopathy, which can sometimes be further exacerbated if the patient is taking vasoactive medications, as is common in those who have these disorders. Conditions such as aortic stenosis and severe hypertrophic cardiomyopathy may cause mechanical outflow obstruction from the left ventricle, especially during exertion [13] . However, aortic stenosis can also cause syncope via inappropriate reflex vasodilatation [6] .
Initial evaluation of patients with suspected cardiac syncope
As mentioned above, there are a number of findings of the medical history, physical examination or ECG that should alert to the possibility of a cardiac cause of syncope. A number of studies have been conducted to determine which factors in the clinical history may predict a serious cause of syncope. Calkins et al. found that male gender, age over 45 years and no more than two episodes of syncope predicted either VT or atrioventricular block as the cause of syncope [14] . In addition, syncope whilst supine, duration of symptoms less than 4 years and blurred vision were reported to be independent predictors of cardiac syncope [15] . Furthermore, Sheldon et al. demonstrated that male gender and age at onset of syncope over 35 years predicted VT as the syncopal cause rather than a neurocardiogenic aetiology [16] .
Clinical risk scores have been developed to predict the outcome in patients presenting with syncope [1, [17] [18] [19] . Many of these risk scores have key common factors that increase the risk of a poor outcome, including abnormal ECG, age above 40 years and history of heart failure or myocardial infarction, which highlights the importance of structural heart disease in the prognosis of syncope.
The initial evaluation is therefore critical in patients with syncope. A clinical history, physical examination and ECG should always be conducted if there is suspicion of cardiac syncope. Further diagnostic work-up is guided by the findings of the initial evaluation.
History
The evaluation of syncope begins with a thorough clinical history. This includes a detailed assessment of the syncopal event including prodromal symptoms and the immediate aftermath. In particular patients should be asked how they felt upon awakening after loss of consciousness as this can be helpful in differentiating between syncope and other causes of loss of consciousness, such as seizures. The absence of prodromal symptoms can be consistent with syncope due to arrhythmia, especially bradyarrhythmia. Chest pain, shortness of breath and tachypalpitations are also indicative of cardiac syncope. The observations of witnesses to the event are often helpful.
Physical examination
Soon after the event, a detailed physical examination should be carried out, including measurement of blood pressure (both supine and standing). In particular, the cardiovascular examination should include evaluation of jugular venous distension, murmurs or additional heart sounds on cardiac auscultation and displaced point of maximal impulse. Carotid artery auscultation should also be performed for evaluation of bruit and the quality of the carotid pulse. Lung auscultation should determine the presence of rales and the respiratory rate and pattern. The quality of peripheral pulses needs to be evaluated. A neurological examination should be performed to assess any abnormalities of cognition, speech, motor strength, sensation or visual fields.
ECG
The 12-lead ECG is an important tool in the initial evaluation of syncope. The ECG can provide information about heart rate and rhythm, and the presence of ongoing ischaemia (T wave changes or ST depression) or a new infarction (ST elevation). In addition, the presence of Q waves should be noted as an indication of a prior myocardial infarction or a myocardial scar. Changes suggestive of left ventricular hypertrophy might be present on the ECG. The QT interval should be measured and evaluated for abnormally long or short QT intervals. The presence of a delta wave, Brugada pattern, bundle branch block or atrioventricular conduction abnormalities should also be noted. It is important to acknowledge that some of the ECG changes associated with these disorders may only be present intermittently and therefore one ECG may not be enough to rule them out. Arrhythmogenic right ventricular cardiomyopathy is a relatively rare disorder with ECG characteristics of T wave inversion in the anteroseptal leads and epsilon waves.
Blood tests
Whilst blood tests are generally not considered a valuable part of the diagnosis of syncope, a complete blood count and electrolyte levels should be measured in most instances. In selected patients, if there is suspicion of acute ischaemia or infarction, cardiac biomarkers, preferably a troponin, should be evaluated. In some cases, more than one troponin test may be needed to rule out myocardial infarction. If a pulmonary embolus is suspected, measurement of D-dimer levels may be helpful.
Echocardiogram
The echocardiogram is a relatively simple noninvasive test that can easily be performed at the bedside, even in the emergency department. This test can provide useful information, especially if structural heart disease is suspected or if a patient with known heart disease presents with syncope. The echocardiogram provides a good estimate of left ventricular function, including signs of regional wall motion abnormalities that are consistent with coronary artery disease. In addition, left ventricular size and thickness are readily visualized by this technique. The presence of valvular heart disease, including aortic stenosis, can be evaluated. Tricuspid regurgitation, particularly if accompanied by dilatation of the right ventricle, raises suspicion of a pulmonary embolus. Right ventricular dilatation and thinning of the wall may be present in conditions such as arrhythmogenic right ventricular cardiomyopathy.
ECG monitoring
Individuals with syncope who have evidence of structural heart disease are candidates for hospital admission for continuous telemetry. Holter monitoring, for 24 h or longer, is frequently used for further evaluation of heart rate and rhythm in patients with syncope. The implantable loop recorder, a small wireless monitor placed subcutaneously in the chest, is becoming increasingly used for long-term ECG monitoring. Storage of ECG tracings can be activated either by prespecified criteria or by the patients during symptoms. This is a promising tool for use in those with recurrent syncope of unknown cause [20] . The battery of the most recent loop recorders can last for up to 36 months. It is very important when interpreting the results of rhythm monitoring to correlate symptoms with the results of the ECG tracings.
Syncope in patients with suspected or known coronary artery disease
The presence of ischaemic heart disease increases the risk of syncope being due to ventricular arrhythmias. This, in particular, applies to individuals with a left ventricular ejection fraction of less than 35%-40%. The risk of death in patients with syncope and coronary artery disease is directly proportional to the severity of left ventricular dysfunction [5] .
The evaluation of patients with syncope who are at risk of coronary artery disease should include an evaluation for myocardial ischaemia as well as for the signs of previous myocardial infarction. The choice of initial tests may vary according to the presentation and the level of suspicion of ischaemia, but might include exercise stress testing or a myocardial perfusion imaging study. It is noteworthy that syncope can be the only presenting symptom of myocardial infarction in elderly patients.
In patients with coronary artery disease and a severely depressed ejection fraction (<35%), who present with syncope, the risk of malignant arrhythmias is such that an implantable cardioverter defibrillator (ICD) may be indicated regardless of the perceived aetiology of the event [21] . Even in the absence of syncope, an ICD has been shown to improve mortality in this particular group of patients [22, 23] , and therefore invasive electrophysiology study for risk stratification with regard to VT is not required. Such a study can, nevertheless, help to determine a specific diagnosis, although in a patient with noninducible arrhythmias a device is still indicated. On the other hand, if there is a history of coronary artery disease, even with prior myocardial infarction, but the ejection fraction is preserved (>35%-40%), a cardiac electrophysiology study may be indicated for further risk stratification. The prognosis of patients with a normal electrophysiological result, under these circumstances, is favourable [24] .
An electrophysiology study is performed by placing catheters in the right-sided chambers of the heart via venous puncture, usually in the groin. Programmed stimulation of the ventricles is used to evaluate the risk of developing VT [25] . Although the induction of monomorphic VT is considered a definite abnormality, the induction of ventricular fibrillation is nonspecific. Sinus node function and atrioventricular conduction are also tested, but the sensitivity for these abnormalities is poor [26] . Inducibility of VT is associated with a high risk of sudden cardiac death whereas noninducibility predicts a low risk of sudden cardiac death [27] . The value of the electrophysiology study in patients with normal left ventricular function and no coronary artery disease is relatively low [28] .
It is worth noting that ICD-treated patients remain at risk of syncope because only the risk of sudden cardiac death is being assessed. This implies the need for identification of the precise mechanism of syncope in these patients and specific treatment if possible [6] .
In patients with coronary artery disease, if the suspicion of a brady-or tachyarrhythmia is high despite a normal electrophysiological evaluation, an implantable loop recorder may be considered.
Syncope and nonischaemic dilated cardiomyopathy
Nonischaemic dilated cardiomyopathy, where left ventricular function is reduced due to reasons other than as a consequence of coronary artery disease, can also be associated with syncope. Likely causes are ventricular arrhythmias, bradyarrhythmias and orthostatic hypotension, either due to a decreased cardiac output or as a side effect of the medications used to treat the dilated cardiomyopathy. Syncope is an ominous sign in this population; in one series, almost half of the patients presenting with this symptom had died suddenly within 1 year of presentation [29] . It is interesting that in this same study, 70% of those who presented with VT or sudden cardiac death had a prior syncopal event.
As with ischaemic cardiomyopathy, an ICD is indicated for those who have an ejection fraction of less than 35% [21] . However, the data on the mortality benefit of a defibrillator are not as robust for nonischaemic as for ischaemic cardiomyopathy. The DEFINITE trial enrolled only patients with nonischaemic heart failure and, although there was a significant reduction in sudden death, there D. O. Arnar Review: Syncope in heart disease was only a borderline significant reduction in overall mortality [30] .
Invasive electrophysiology assessment is not as helpful a risk stratification tool for those with nonischaemic cardiomyopathy as for those with coronary artery disease. In a small study of patients with nonischaemic cardiomyopathy, unexplained syncope, a normal electrophysiology study, and who were subsequently treated with an ICD, 50% received appropriate therapy with a defibrillator in the first 2 years after implantation [31] . Thus, the implications of a normal electrophysiology study in patients with nonischaemic cardiomyopathy are not as clear as for those with coronary artery disease and preserved ejection fraction.
As for patients with ischaemic cardiomyopathy, an implantable loop recorder may be considered in those with nonischaemic cardiomyopathy in whom left ventricular function is relatively preserved (>35%-40%), when detailed evaluation has not demonstrated abnormalities, but arrhythmias are still strongly suspected.
Syncope in hypertrophic cardiomyopathy
Hypertrophic cardiomyopathy is a relatively common (1 : 500) inherited disease that is caused by mutations in genes encoding sarcomere proteins [32, 33] . There are different forms of hypertrophy of the left ventricle, but asymmetric septal hypertrophy is the most common. This type involves primarily the proximal and mid portion of the interventricular septum. The disease is suspected if the ECG shows signs of hypertrophy with inverted T waves in the precordial leads, particularly when the degree of myocardial thickness is severe. The condition is then confirmed by an imaging study, usually either echocardiography or cardiac magnetic resonance imaging (MRI).
In hypertrophic cardiomyopathy, the normal cellular architecture is disrupted in the hypertrophied area, and extensive fibrosis (frequently seen as late gadolinium enhancement on MRI) can increase the risk of malignant ventricular arrhythmias [34] . This can lead to syncope or even sudden cardiac death. The occurrence of syncope (particularly within the previous 6 months) in hypertrophic cardiomyopathy is serious and increases the risk of sudden cardiac death five-fold [35] . Other risk factors for serious arrhythmias include prior history of resuscitated cardiac arrest, family history of sudden death, nonsustained VT, marked ( 30 mm) hypertrophy and decreased blood pressure with exercise [35] . Invasive electrophysiology assessment is not particularly helpful for risk stratification of this condition.
Despite the high risk of ventricular arrhythmias in hypertrophic cardiomyopathy, syncope in this disorder can be caused by a variety of mechanisms. Individuals with hypertrophic cardiomyopathy are at increased risk of atrial fibrillation which can impact the clinical course of the disease [36] . Impaired left ventricular relaxation and heart failure can result in left atrial enlargement and atrial fibrillation. The latter is associated with increased morbidity and mortality due to loss of active diastolic left ventricular filling and decreased diastolic filling time with rapid ventricular rates.
Patients with severe obstruction of the left ventricular outflow tract may experience syncope during exercise.
The main treatment for patients at high risk of sudden death is an ICD. This device is recommended for patients resuscitated from sudden cardiac death or sustained ventricular tachycardia and is considered a reasonable option if there is a family history of sudden cardiac death, maximum wall thickness of 30 mm or recent unexplained syncope [35] . In those with nonsustained VT or an abnormal blood pressure response to exercise, an ICD might be useful in certain circumstances. Beta blockers are frequently prescribed and drugs such as amiodarone and disopyramide may also be useful in certain situations.
Arrhythmogenic right ventricular cardiomyopathy and syncope
Arrhythmogenic right ventricular cardiomyopathy is a relatively rare disease that is associated with family clustering and characterized by fibrous and fatty replacement of the right ventricular myocardium [37] . The fatty/fibrous tissue may be a substrate for ventricular arrhythmias causing syncope or even sudden cardiac death. Arrhythmogenic right ventricular cardiomyopathy usually affects only the right ventricle although occasionally the left ventricle can also be involved. This condition may be the cause of up to one-fifth of sudden deaths in individuals under the age of 35 years [5] . Syncope or sudden death may be the first manifestation of the disease. 
Syncope in aortic stenosis
Aortic stenosis is a disorder of calcific degeneration of the aortic valve and, with the ageing of Western populations, has become the most common valvular heart disease in Europe. Syncope is usually a sign of advanced aortic stenosis. The cause of syncope in patients with advanced aortic stenosis is likely to be multifactorial. In general, syncope with aortic stenosis occurs with exercise. It has been presumed that the reduced degree of valve opening inhibits the necessary increase in cardiac output whilst peripheral vascular resistance falls on exertion. Other proposed mechanisms include a vasodepressor response which is triggered by increased left ventricular pressure during exercise in patients with aortic stenosis [13, 38] . Although severe aortic stenosis is relatively rare amongst individuals who present with syncope, it is an important potential diagnosis and usually suspected after clinical examination including cardiac auscultation. The diagnosis is confirmed by echocardiography. The treatment is, in most cases, valve replacement.
Primary electrophysiological disorders
Although primary electrophysiological disorders are not in fact structural heart diseases, they are important causes of cardiac syncope, particularly in young individuals. These disorders include the inherited channelopathies, LQTS, short QT syndrome and Brugada syndrome. Whilst they can all be diagnosed with an ECG, the findings may be subtle and dynamic. Pharmacological provocation can be helpful if there is suspicion of or Brugada syndrome, but the ECG does not show typical type 1 changes.
Catecholaminergic polymorphic ventricular tachycardia is most frequent due to an inherited defect in the ryanodine receptor in cardiac myocytes. This defect increases the risk of polymorphic VT during exertion or with elevated heart rates [39] . There are no distinct abnormalities on the resting ECG, but polymorphic VT can be seen during an exercise stress test. An ICD is commonly used to treat highrisk patients with a primary electrophysiological disorder.
The future: a role for genetics?
Genetic testing for various disorders that can cause syncope, including the most common mutations causing LQTS, has become readily available. In addition, tests for mutations associated with Brugada syndrome and catecholaminergic polymorphic VT have become commercially available. Testing for sarcomeric mutations involved in hypertrophic cardiomyopathy and desmosomal protein mutations in arrhythmogenic right ventricular cardiomyopathy is also possible.
At present, the optimal use of genetic testing in patients who have survived a cardiac arrest or had a suspected cardiac syncopal event is still undecided. However, genetic testing has been used postmortem (molecular autopsy) in cases in which the apparent cause of sudden death is unknown, but a primary arrhythmia suspected based on the clinical circumstances and lack of evidence of structural heart disease. Recently, in a large series of unexplained cardiac sudden deaths, genetic testing achieved a diagnosis in 34% of cases that would otherwise have remained unexplained [40] . The Heart Rhythm Society and the European Heart Rhythm Association have recently issued an expert consensus statement on the use of genetic testing for channelopathies and cardiomyopathies [41] . In this comprehensive document, the indications for genetic testing for these disorders are reviewed.
There have been further advances in the understanding of the potential genetic contribution to common causes of syncope such as sick sinus syndrome as well as variants that modulate important electrophysiological parameters such as heart rate, PR interval and QRS duration [42, 43] . Whether or how this will influence future approaches to common problems such as syncope remains unclear (Fig. 1) , but it is likely that genetic information will play an increasing role in medical decision making in the coming decades.
Summary
In patients who present with syncope, the presence of structural heart disease should be considered and further cardiac evaluation performed as indicated by the clinical history, physical examination and ECG findings. The presence of structural heart disease in patients with syncope is associated with a poor prognosis and may be a predictor of sudden cardiac death. A family history of sudden cardiac death, especially at a young age, should always be noted in individuals with syncope, as this may be an indicator of an inherited disorder that could lead to life threatening arrhythmias.
